Electromed, Inc. (ELMD) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance, with significant revenue and net income growth, improved gross margins, and efficient cash management. Positive developments include successful sales team expansion, effective CRM implementation, and promising hospital channel growth. The Q&A section reveals favorable analyst sentiment and market expansion opportunities, despite some management vagueness. The company's proactive strategies, including share repurchases and manufacturing optimization, support a positive outlook. Overall, the combination of strong earnings, optimistic guidance, and strategic initiatives suggests a positive stock price movement over the next two weeks.
Key Financial Performance
Quarterly Revenue $17.4 million, a 17% year-over-year growth. This was driven by growth across all key markets, including a 15% increase in the Core Home Care segment, 60% growth in the Hospital segment, and 76% growth in the Distributor Channel due to strong demand from DME partners.
Annual Revenue $64 million, a 17% increase from $54.7 million in the prior year. This growth was attributed to an increase in direct sales representatives and higher net revenues per approval.
Operating Income $3 million in Q4, marking a 30% increase year-over-year. This was due to improved operating leverage of 174 basis points over Q4 last year.
Net Income $2.2 million in Q4, a 21% increase year-over-year. This translated to a diluted earnings per share of $0.25, a 24% increase versus the prior year.
Gross Profit $50 million for the fiscal year, representing 78.1% of net revenues, up from $41.7 million (76.3% of net revenues) in the prior year. The increase was due to higher net revenue per device and increased revenue.
SG&A Expenses $39.3 million for the fiscal year, a 14% increase from $34.5 million in the prior year. This was primarily due to accelerated recognition of share-based compensation and higher salaries and incentive compensation.
Pretax Income $10.3 million for the fiscal year, a significant increase from the prior year, driven by higher net revenues and gross profit.
Net Income (Annual) $7.5 million for the fiscal year, translating to an EPS of $0.85 per diluted share.
Cash Position $15.3 million as of June 30, 2025, reflecting a decrease of $0.8 million from the prior year. The decrease was due to $10 million in share repurchases and $2.3 million in taxes paid, offset by $11.4 million in cash generated from operating activities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
SmartVest HFCWO Therapy: Highlighted as a key component in treating bronchiectasis, with a focus on airway clearance, infection treatment, and inflammation reduction. The company is actively promoting awareness through campaigns and clinical evidence.
Market Expansion: Achieved record revenue of $64 million in FY 2025, with significant growth in Home Care (15%), Hospital (60%), and Distributor Channel (76%). Expanded direct sales team to 55 representatives and plans to grow to 61 territories in FY 2026.
Operational Efficiencies: Implemented a new CRM system to enhance sales productivity and market insights. Achieved 0 back orders with a 99% first pass yield. Introduced SmartOrder E-prescribe Solution, with 38% of orders now processed through it.
Strategic Shifts: Focused on penetrating the bronchiectasis market, targeting undiagnosed patients and increasing awareness through campaigns and clinical presentations. Expanded leadership roles in marketing, payer access, and IT to support growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff-related risks: Although Electromed is largely insulated from tariff-related turbulence due to its U.S.-based operations and domestic suppliers, there is a potential risk from upstream supply chain exposure of its suppliers to tariffs. This could impact costs and operational efficiency.
Supply chain disruptions: While the company has maintained 0 back orders and lean inventory levels, any disruptions in the supply chain could affect its ability to meet demand and maintain operational performance.
Market penetration challenges: Despite efforts to address the large unrecognized market for bronchiectasis treatment, there remains a significant gap in awareness and diagnosis, which could limit the company's growth potential in this segment.
Operational scalability: The company is expanding its sales team and implementing new systems like CRM and SmartOrder E-prescribe Solution. However, scaling operations to meet growing demand could pose challenges in maintaining efficiency and service quality.
Regulatory and reimbursement risks: The company operates in a highly regulated environment, and any changes in healthcare regulations or reimbursement policies could adversely impact its financial performance and strategic objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Fiscal Year 2026 Home Care Revenue Per Representative: Electromed expects Home Care revenue per representative to range between $1 million and $1.1 million, an increase from the fiscal year 2025 performance of $1,058,000 per representative.
Expansion of Sales Territories: The company plans to expand its home care sales territories to as many as 61 across the U.S. in fiscal year 2026, up from 55 territories in fiscal year 2025.
Manufacturing Optimization Plan: Electromed has initiated a manufacturing optimization plan to add new capacity, with completion expected in early fiscal year 2026.
SmartOrder E-prescribe Solution Adoption: The company aims to increase the adoption of its SmartOrder E-prescribe Solution, which accounted for 38% of orders in Q4 fiscal year 2025, to improve operational efficiency and order processing.
Bronchiectasis Market Penetration: Electromed is targeting the large unrecognized market for bronchiectasis treatment, with plans to complete a manuscript on HFCWO therapy prescribing guidelines by Q1 fiscal year 2026.
Operational and Financial Outlook for Fiscal Year 2026: The company anticipates delivering double-digit top-line growth, expanded operating leverage, and strong operating cash flows in fiscal year 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Stock Repurchase Program: In Q4, Electromed successfully completed its second $5 million stock repurchase program of fiscal year 2025. This demonstrates the company's confidence in its future and its commitment to enhancing shareholder value.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What contributed to the strong gross margin in the quarter?
A:The strong gross margin was attributed to higher net revenue per device, driven by favorable mix within the Home Care revenue channel, which is a high-margin area. The mix of payer targets across commercial versus Medicare worked in their favor, resulting in over 78% gross margins for the year.
Q:What caused the strong hospital channel revenue?
A:The hospital channel revenue growth was attributed to investments in hospital-focused sales reps and the dynamics of the hospital market. The hospital is seen as a gateway to home care, as patients using the technology in hospitals may continue using it at home after discharge. The sales cycle in hospitals is longer due to capital equipment sales, but it presents a significant opportunity.
Q:Are there increased awareness and potential tailwinds around bronchiectasis due to new entrants in the market?
A:Yes, the introduction of a new drug by Insmed has raised awareness about bronchiectasis, an underserved and underdiagnosed disease. The drug targets inflammation but does not clear airways, which aligns with the company's technology for airway clearance. Increased awareness is expected to benefit the market.
Q:What is the impact of the manufacturing optimization plan?
A:The manufacturing optimization plan is expected to expand capacity and reduce movement in manufacturing operations, enabling growth within the existing footprint for the next three years. It is not expected to significantly impact margins due to offsetting factors like wage increases and potential tariffs.
Q:What are the expectations for hospital revenue growth and team expansion?
A:Hospital revenue growth is expected to exceed double digits, albeit on a smaller base compared to home care. The company plans to expand the hospital-focused team cautiously, ensuring a successful algorithm for growth before adding more representatives.
Q:How has the new CRM system implementation impacted the sales force?
A:The new CRM system, implemented on time and on budget, has been well-received. It integrates sales and reimbursement team data, providing better access to information and improving productivity. Feedback from the sales team has been positive, and the system is expected to become a stronger asset over time.
Q:What is the impact of E-prescribe availability on prescribing habits?
A:E-prescribe availability has made the prescription process easier and faster, reducing the average days to ship and time to approve prescriptions. Clinics that have adopted it have seen benefits, and the company is focused on sustaining this behavior.
Q:What has been the response to VA-specific marketing efforts?
A:VA-specific marketing efforts have been successful, contributing over $1 million to hospital revenue last year. Prescriptions from the VA act like capital equipment sales, and the company plans to continue targeting this market segment.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the question about historical examples of market acceleration due to increased awareness, stating they did not have a proxy to give. Additionally, the response to the question about VA-specific marketing efforts lacked detailed data and was somewhat vague.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Anderson Schock
Australia bronchiectasis
Bauser ROTH
Ben Hayner
Bronchiectasis Conference
CMS guideline
Cunniff President
DME
Electromed today
HFCWO therapy
Home Care
Inc
Nagel
Research Division
United States
age order
baseline
clinic
commitment
completion
component
disease process
education
exposure
order SmartOrder
patient bronchiectasis
prescribing
profitability
sale productivity
segment
tariff
therapy opportunity
ELMD Transcript
Electromed, Inc. (ELMD) Q3 2026 Earnings Call Transcript
Positive5-12
Electromed's earnings report shows strong financial performance with a 10% revenue growth and a 20% increase in net income, supported by improved gross margins and operational efficiencies. Despite a slight increase in operating expenses, the company's financial health remains robust with increased cash flow. The absence of negative insights from the Q&A session further supports a positive outlook. These factors suggest a likely positive stock price movement over the next two weeks.
Electromed, Inc. (ELMD) Q2 2026 Earnings Call Transcript
Positive2-10
The earnings report shows strong financial metrics with revenue, operating income, and EPS all increasing significantly. The company's strategic focus on expanding its sales force and product awareness has paid off, particularly in the homecare segment. The approval of a stock repurchase plan and actual buybacks signal confidence in future prospects. While SG&A expenses have risen, the overall financial health remains robust. The Q&A session highlighted growth opportunities and strategic initiatives. Despite minor concerns about rep productivity, the strong financial performance and strategic initiatives suggest a positive stock price movement.
Electromed, Inc. (ELMD) Q1 2026 Earnings Call Transcript
Positive11-12
The earnings call highlights strong financial performance with a 15% revenue increase and 38% rise in operating income. The strategic expansion of sales territories and focus on the bronchiectasis market are promising. The $10 million stock repurchase program indicates confidence in the company's value. However, economic uncertainties and unclear management responses about hospital sales create slight concerns. Overall, the sentiment is positive due to strong growth metrics, strategic initiatives, and shareholder returns.
Electromed, Inc. (ELMD) Q4 2025 Earnings Call Transcript
Positive8-26
The earnings call highlights strong financial performance, with significant revenue and net income growth, improved gross margins, and efficient cash management. Positive developments include successful sales team expansion, effective CRM implementation, and promising hospital channel growth. The Q&A section reveals favorable analyst sentiment and market expansion opportunities, despite some management vagueness. The company's proactive strategies, including share repurchases and manufacturing optimization, support a positive outlook. Overall, the combination of strong earnings, optimistic guidance, and strategic initiatives suggests a positive stock price movement over the next two weeks.
ELMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
